RE: DosemeRX Tool / Current State of Play13 Aug 2025 13:29
King H
Good afternoon, certainly DoseMeRx opens up a completely new avenue, on top of the current diversification of clients and drug targets.
I agree with your number/breakeven
APTA £14mlnncap and £1.2mln full year revs( = x 12 annual rev)
FAB £17 mln and £1.7mln full year ( x 10)
PYC £1.4mln and £0.85mln full year ( x less than 2 )